UK markets open in 6 hours 11 minutes

Eli Lilly and Company (0Q1G.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
540.00+295.04 (+120.45%)
At close: 04:18PM BST
Full screen
Loading interactive chart…
  • Investor's Business Daily

    Is Eli Lilly Stock A Buy Or A Sell After FDA Delays Its Alzheimer's Drug Decision?

    The FDA will now hold an advisory committee meeting to discuss Eli Lilly's Alzheimer's drug, donanemab. Is Eli Lilly stock a buy or a sell?

  • Yahoo Finance Video

    Weight-loss drug shortage result of 'unprecedented demand'

    Certain doses of Eli Lilly's (LLY) GLP-1 weight loss drugs Zepbound and Mounjaro are facing a supply shortage, much like competitor Novo Nordisk's (NVO) own weight-loss treatment Wegovy. Eli Lilly is now considering releasing vials of their treatments for consumers capable of self-administering the drug. The #ReleaseTheVials campaign across social media is pressuring the pharmaceutical company to go this route for quicker, easier consumer access. On The Pen Live Host Dave Knapp talks about his experience using various treatment methods after a Type 2 Diabetes diagnosis and the major supply and demand imbalances occurring around the pharmaceutical trend. "Even though... you've seen them [Eli Lilly] announce major investments in the United States in manufacturing... they just can't keep up with 100,000 precipitations a week. You saw Eli Lilly and Zepbound specifically eclipse Wegovy..." Knapp tells Yahoo Finance. "You saw Zepbound eclipse Wegovy for the first time in new prescriptions just a week ago. And there's just no way they can keep up with that when you consider the complexity of the pens and the manufacturing of these very, very difficult — [Eli Lilly CEO] Dave Rick's own words — some of the most complex things to manufacture in the country." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.

  • Yahoo Finance Video

    Don't 'run away' from tech, but do broaden out: Strategist

    Yahoo Finance Live revisits the calls made at the end of last year to see which hold up and which are in need of repositioning. Laffer Tengler Investments CEO & CIO Nancy Tengler and Great Hill Capital Chairman and Managing Member Thomas Hayes join Yahoo Finance to revisit and update last year's calls. Hayes outlines his market strategy amid a surging market: "We've been publicly bullish nonstop for a year and a half, and we've recently become more cautious. We're up 17 out of the last 21 weeks. No 2% pullback in the last 100 trading days. So, in recent weeks, we put on a 2% hedge: 1% put spreads on the S&P, 1% put spreads on the semiconductor index, and 98% long. So if we're right, those have an expected value of 5x each." Tengler addresses risks on her radar: "We started broadening out the portfolio, really to have the improvement in some of the names that we've seen in healthcare, financials, some of the more cyclical names...But my biggest concern is that the Fed seems to be, I guess, walking away from their data dependence, and I'll put quotes around that, that they've had in the past. And it seems they're determined to cut. We've drawn an analogy to the 90s. We think you can have higher inflation, but not materially higher. So that's my worry, that we get a surge in inflation because the Fed is too easy." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino